NAD+ Boosters

Disclaimer: The information presented in this section is for educational and informational purposes only. It is not intended as medical advice. No supplement discussed on this site has been proven to prevent, stop, or reverse neurodegenerative disease. While some supplements have been studied for their potential to support aspects of cellular function, any observed effects are generally modest, variable between individuals, and highly context-dependent. Before starting any supplement, consult with a qualified healthcare professional. Appropriate professionals may include a physician, neurologist, pharmacist, nurse practitioner, physician assistant, or registered dietitian. This does not refer to wellness influencers, supplement sellers, health coaches, or practitioners without medical training in pharmacology, neurology, and drug-supplement interactions. Supplements may interact with medications or produce unintended side effects. The inclusion of any supplement on this site does not constitute a recommendation for use. Descriptions of mechanisms or research findings are provided to improve understanding of current scientific investigation, not to guide individual treatment decisions.

Overview

NAD+ boosters usually refer to compounds such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that are intended to raise levels of NAD+, a central cofactor in cellular energy metabolism and stress responses. In the neurodegeneration space, they are often claimed to support mitochondrial function, improve cognition, slow aging-related decline, or enhance neuronal resilience.

NAD+ boosters are mechanistically attractive and still clinically early. They are more credible than many wellness-style supplements because they map onto real aging and mitochondrial biology, but they are not yet established neurodegenerative disease therapies.

Proposed Mechanisms

The biologic rationale centers on the fact that NAD+ is critical for energy production, redox balance, DNA damage responses, SARM1 inhibition, and sirtuin/PARP-linked stress pathways. Because mitochondrial dysfunction and metabolic stress are common themes in neurodegeneration, raising NAD+ has been proposed as a way to improve neuronal resilience.

Preclinical work has often shown encouraging signals, including improved cognition or neuropathology in animal models of neurodegenerative disease. That said, one of the key translational questions is whether oral precursors meaningfully raise brain NAD+ in humans, not just blood levels. A recent pharmacokinetic study suggests systemic NAD+ can rise without clear short-term evidence of brain NAD+ elevation after brief dosing, which is an important caution point.

Evidence Summary

Preclinical: The preclinical case is fairly strong. Reviews published in 2025 describe consistent neuroprotective and behavioral benefits in in vivo models, particularly around bioenergetics, inflammation, and neuronal survival.

Translational / RCT / observational: Human data remain early and mixed. A 2025 review of human clinical trials found that NR and related precursors do reliably raise circulating NAD+-related biomarkers, but cognitive and clinical benefits are still uncertain and based on small studies. The 2025 review of NR supplementation and cognition similarly found limited and heterogeneous human evidence.

Evidence level

Low-to-moderate overall.

NAD+ boosters have a stronger mechanistic rationale than many supplements and a better translational logic than purely antioxidant products, but they do not yet have large, convincing clinical evidence showing meaningful slowing of neurodegenerative disease.

Limitations

The biggest limitations are target engagement in the brain, small trial sizes, and the gap between biomarker movement and real clinical benefit. Raising blood NAD+ is not the same thing as proving improved neuronal function or reduced neurodegeneration.

Another limitation is disease specificity. These compounds may make the most sense in disorders where metabolic stress is central, but that remains more of a hypothesis than a demonstrated clinical rule.

Safety and Considerations

NAD+ precursors are generally presented as well tolerated in early human studies, but long-term safety, optimal dosing, and disease-specific use are still being worked out.

Sources

Conlon NJ et al. “The Role of NAD+ in Regenerative Medicine.” 2021.
Fricker RA et al. “The Influence of Nicotinamide on Health and Disease in the Central Nervous System.” 2018.
Gallagher C, Emmanuel OO. “NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.” Ageing Research Reviews. 2026.
Khatri S, Sedej S. “Clinical evidence for the use of NAD+ precursors to slow aging.” Geromedicine. 2025.